Peregrine Pharmaceuticals to Report Third Quarter Fiscal Year 2014 Financial Results Before Market Open on March 7, 2014
February 27 2014 - 4:00PM
Marketwired
Peregrine Pharmaceuticals to Report Third Quarter Fiscal Year 2014
Financial Results Before Market Open on March 7, 2014
TUSTIN, CA--(Marketwired - Feb 27, 2014) - Peregrine
Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage
biopharmaceutical company developing first-in-class monoclonal
antibodies focused on the treatment and diagnosis of cancer, today
announced that it will report financial results for the third
quarter of fiscal year (FY) 2014 on March 7, 2014 before market
opens and will host a conference call and webcast at 8:00 a.m.
Pacific Time (11:00 a.m. Eastern Time). Peregrine's senior
management will discuss financial results for the third quarter
ended January 31, 2014 of FY 2014 and will review recent progress
of its clinical development programs.
To listen to the live webcast, or access the archived webcast,
please visit: http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or
(253) 237-1126 and request the Peregrine Pharmaceuticals call. A
replay of the call will be available starting approximately two
hours after the conclusion of the call through March 14, 2014 by
calling (855) 859-2056, or (404) 537-3406 and using passcode
4248303.
About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc.
is a biopharmaceutical company with a portfolio of innovative
monoclonal antibodies in clinical trials focused on the treatment
and diagnosis of cancer. The Company is pursuing multiple clinical
programs in cancer with its lead immunotherapy candidate
bavituximab while seeking a partner to further advance its novel
brain cancer agent Cotara®. Peregrine also has in-house cGMP
manufacturing capabilities through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found at
www.peregrineinc.com.
Contact: Christopher Keenan or Jay Carlson Peregrine
Pharmaceuticals, Inc. (800) 987-8256 info@peregrineinc.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024